Acute Maniform Reaction to a Single Dose of Escitalopram in a Social Phobic Patient – An Atypical Jitteriness Syndrome?

 

 Buy Article Permissions and Reprints

We report an unusual acute mental side-effect [4] of the selective serotonin reuptake inhibitor (SSRI) escitalopram in a 23-year-old male student of mathematics, who has suffered from severe social fears and avoidance behaviour since kindergarten. He was diagnosed with social anxiety disorder (DSM-IV) and admitted for in-patient therapy. A structured diagnostic interview (SCID) revealed no psychiatric comorbidity, physical examination and laboratory work-up showed no peculiarities besides slight obesity. About one hour after the first dose of escitalopram (5 mg) he unexpectedly became giddy, chatty, kidding, vociferous, uncommonly gregarious, restless, incapable of controlling his thoughts and actions. After eight hours the symptoms subsided without any pharmacological intervention; escitalopram treatment was stopped. The patient abnegated intake of illegal drugs, no such substances could be detected in his blood or urine. One week later, when escitalopram was initiated a second time, only short-lived motor restlessness, trembling, fidgetiness and difficulty in concentrating emerged, but no maniform symptoms. Escitalopram was gradually increased to 15 mg/d without further side-effects during the following six weeks.

Although it was assumed that a subset of social phobic patients might belong to the bipolar spectrum [3] [6] and overshoot during SSRIs in a hypomanic direction [2], the further course of this patient does not corroborate this possibility. Symptoms of behavioural activation and agitation have been reported in adolescent anxiety disorder patients after SSRIs [5], but only after a longer duration of treatment. The authors presume an underlying neuromaturational vulnerability and, of note, our patient possibly had suffered from night terrors as a child. We hypothesize that his initial symptoms might be an atypical manifestation of the “jitteriness syndrome” [1], which he experienced in a typical way during re-challenge with escitalopram. Agitation or jitteriness after acute SSRIs is possibly mediated by activation of 5-HT2C receptors [2]. However, we are not aware that brief maniform symptoms have so far been described as an atypical manifestation.

References

• 1 Amsterdam JD, Hornig-Rohan M, Maisling G. Efficacy of alprazolam in reducing fluoxetine-induced jitteriness in patients with major depression.  J Clin Psychiatry. 1994;  55 394-400
  PubMedGoogle Scholar
• 2 Bagdy G, Graf M, Anheuer ZE. et al . Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but nor the 5-HT1A receptor antagonist WAY-100635.  Int J Neuropsychopharmacol. 2001;  4 399-408
  PubMedGoogle Scholar
• 3 Himmelhoch JM. Social anxiety, hypomania and the bipolar spectrum: data, theory and clinical issues.  J Affect Disord. 1998;  50 203-213
  CrossrefPubMedGoogle Scholar
• 4 Möller HJ, Langer S, Schmauss M. Escitalopram in clinical practice: results of an open-label trial in outpatients with depression in a naturalistic setting in Germany.  Pharmacopsychiatry. 2007;  40 53-57
  Article in Thieme ConnectPubMedGoogle Scholar
• 5 Riddle MA, Hardin MT, King R. et al . Fluoxetine treatment of children and adolescents with Tourette's and obsessive compulsive disorders: preliminary clinical experience.  J Am Acad Child Adolesc Psychiatry. 1990;  29 45-48
  CrossrefPubMedGoogle Scholar
• 6 Valenca AM, Nardi AE, Nascimento I. et al . Do social anxiety disorder patients belong to a bipolar spectrum subgroup?.  J Affect Disord. 2005;  86 11-18
  CrossrefPubMedGoogle Scholar

Correspondence

Dr. C. Muhtz

Clinic for Psychiatry and Psychotherapy

University – Hospital Hamburg – Eppendorf

Martinistraße 52

20246 Hamburg

Germany

Phone: +49/40/7410 564 37

Fax: + 49/40/7410 542 07

Email: cmuhtz@uke.uni-hamburg.de